HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rosiglitazone enhances apolipoprotein M (Apom) expression in rat's liver.

Abstract
Apolipoprotein M (APOM) has been suggested as a vasculoprotective constituent of high density lipoprotein (HDL), which plays a crucial role behind the mechanism of HDL-mediated anti-atherosclerosis. Previous studies demonstrated that insulin resistance could associate with decreased APOM expressions. In agreement with our previous reports, here, we further confirmed that the insulin sensitivity was also reduced in rats treated with high concentrations of glucose; such effect could be reversed by administration of rosiglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ). The present study shows that Apom expression is significantly affected by either rosiglitazone or hyperglycemia alone without cross interaction with each other, which indicates that the pathway of Apom expression regulating by hyperglycemia might be differed from that by rosiglitazone. Further study indicated that hyperglycemia could significantly inhibit mRNA levels of Lxrb (P=0.0002), small heterodimer partner 1 (Shp1) (P<0.0001), liver receptor homologue-1 (Lrh1) (P=0.0012), ATP-binding cassette transporter 1 (Abca1) (P=0.0012) and Pparb/d (P=0.0043). Two-way ANOVA analysis demonstrated that the interactions between rosiglitazone and infusion of 25% glucose solution on Shp1 (P=0.0054) and Abca1 (4E, P=0.0004) mRNA expression was statistically significant. It is concluded that rosiglitazone could increase Apom expression, of which the detailed mechanism needs to be further investigated. The downregulation of Apom by hyperglycemia might be mainly through decreasing expression of Pparg and followed by inhibiting Lxrb in rats.
AuthorsGuanghua Luo, Yuehua Feng, Jun Zhang, Qinfeng Mu, Yuanping Shi, Li Qin, Lu Zheng, Maria Berggren-Söderlund, Peter Nilsson-Ehle, Xiaoying Zhang, Ning Xu
JournalInternational journal of medical sciences (Int J Med Sci) Vol. 11 Issue 10 Pg. 1015-21 ( 2014) ISSN: 1449-1907 [Electronic] Australia
PMID25136257 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Apolipoproteins
  • Apolipoproteins M
  • Apom protein, rat
  • Hypoglycemic Agents
  • Lipocalins
  • Thiazolidinediones
  • Rosiglitazone
Topics
  • Animals
  • Apolipoproteins (metabolism)
  • Apolipoproteins M
  • Gene Expression Regulation (drug effects)
  • Hyperglycemia (metabolism)
  • Hypoglycemic Agents (pharmacology)
  • Lipocalins (metabolism)
  • Liver (drug effects, metabolism)
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Rosiglitazone
  • Thiazolidinediones (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: